Funder
Michael J. Fox Foundation for Parkinson's Research
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. USDHHS, Patient-focused drug development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments (Guidance 3), https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome. (2022).
2. Mammen, J. et al. Mapping meaningful symptoms and impacts of disease to digital outcome measures. J. Parkinsons Dis. 13(4), 589–607. https://doi.org/10.3233/JPD-225122 (2023).
3. Politis, M. et al. Parkinson’s disease symptoms: The patient’s perspective. Mov. Disord. 25, 1646–1651 (2010).
4. Port, R. J. et al. People with Parkinson’s disease: What symptoms do they most want to improve and how does this change with disease duration?. J. Parkinsons Dis. 11, 715–724 (2021).
5. USDHHS, Patient-focused drug development: Methods to identify what is important to patients (Guidance 2), https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-methods-identify-what-important-patients. (2022).